drugset / Trial / NCT04666012
Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers
Non-randomizedSequentialOpen-labelPrevention
Summary
This is a Phase 1/2a clinical trial to assess the safety and immunogenicity of AdCLD-CoV19 in healthy adults.
Timeline
- Start
- 2020-12-29
- Primary completion
- 2021-07-09
- Completion
- 2023-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AdCLD-CoV19 | Vaccine | 2.5e+10 unknown | Intramuscular |
| Subject | AdCLD-CoV19 | Vaccine | 5e+10 unknown | Intramuscular |
| Subject | AdCLD-CoV19 | Vaccine | 1e+11 unknown | Intramuscular |